Profil bibliographique

Joseph K. Park

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

56Publications signalées

1947Citations signalées

3Affiliations récentes

Les institutions déclarées

Advanced Imaging Research (United States)Southwestern Medical Center The University of Texas Southwestern Medical Center

Les domaines associés

Lysosomal Storage Disorders ResearchGlycosylation and Glycoproteins ResearchSexual function and dysfunction studiesCellular transport and secretionCarbohydrate Chemistry and Synthesis

Les publications récentes

Accès ouvert 2026 other OpenAlex

Figure 6 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Enriqueta Felip, Peiwen Kuo, Pilar Garrido, C. Chouaïd et autres

DDR mutations. A, Mutation landscape of the 20 most frequently mutated DDR genes in baseline ctDNA. Kaplan–Meier plots for OS by (B) KEGG DDR mutation status and treatment arm, (C) KEGG DDR and TP53 mutation status with SG, (D) KEGG DDR and …

0 citations

Accès ouvert 2026 other OpenAlex

Figure 5 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Enriqueta Felip, Peiwen Kuo, Pilar Garrido, C. Chouaïd et autres

Potential resistance mutations. A,TP53, STK11, and KEAP1 mutation and KRAS driver alteration landscape. B,TP53, STK11, and KEAP1 mutation status relative frequency by best response to last prior anti–PD-(L)1–containing therapy and treatment arm. Kaplan–Meier plots for OS by treatment arm and (C) TP53, …

0 citations

Accès ouvert 2026 other OpenAlex

Data from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Enriqueta Felip, Peiwen Kuo, Pilar Garrido, C. Chouaïd et autres

Abstract Purpose: This exploratory analysis assessed predictive biomarkers for sacituzumab govitecan (SG) in the open-label, phase III EVOKE-01 study of SG versus docetaxel in non–small cell lung cancer (NSCLC). Patients and Methods: Trophoblast cell-surface antigen (Trop) 2 membrane protein expression was analyzed …

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S3 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Enriqueta Felip, Peiwen Kuo, Pilar Garrido, C. Chouaïd et autres

Response rates by treatment arm and Trop-2 median H-score subgroup in the Trop-2 biomarker evaluable population.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S8 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Enriqueta Felip, Peiwen Kuo, Pilar Garrido, C. Chouaïd et autres

DDR pathway forest plot analysis, adjusted for TP53.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S3 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Enriqueta Felip, Peiwen Kuo, Pilar Garrido, C. Chouaïd et autres

Kaplan-Meier plots for OS for median Trop-2 H-score subgroups by treatment arm among patients with (A) PD/SD and (B) CR/PR as best response to last prior anti-PD-(L)1–containing therapy.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S2 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Enriqueta Felip, Peiwen Kuo, Pilar Garrido, C. Chouaïd et autres

Trop-2 subgroup analysis of OS.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table S2 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Enriqueta Felip, Peiwen Kuo, Pilar Garrido, C. Chouaïd et autres

Representativeness of study patients

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S4 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Enriqueta Felip, Peiwen Kuo, Pilar Garrido, C. Chouaïd et autres

Trop-2 subgroup analysis of PFS.

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S7 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Enriqueta Felip, Peiwen Kuo, Pilar Garrido, C. Chouaïd et autres

Genomic alteration landscape based on the HRR 24-gene list.

0 citations

Accès ouvert 2026 other OpenAlex

Figure 4 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Enriqueta Felip, Peiwen Kuo, Pilar Garrido, C. Chouaïd et autres

Oncogenic driver alterations. A, ctDNA oncogenic driver alteration landscape at baseline showing only cases harboring an alteration. Kaplan–Meier plots for OS by (B) KRAS mutation status and treatment arm, (C) EGFR, ALK, ROS1, and RET combined mutation status based on ctDNA only …

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Figure S6 from Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non–Small Cell Lung Cancer: Insights From the EVOKE-01 Study

Enriqueta Felip, Peiwen Kuo, Pilar Garrido, C. Chouaïd et autres

Mutation landscape of the 20 most frequently mutated DDR genes in baseline ctDNA for patients with (A) nonsquamous and (B) squamous histology, adjusted for TP53.

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.